ANI Pharmaceuticals Inc. (ANIP)’s Financial Results Comparing With Fate Therapeutics Inc. (NASDAQ:FATE)

ANI Pharmaceuticals Inc. (NASDAQ:ANIP) and Fate Therapeutics Inc. (NASDAQ:FATE) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ANI Pharmaceuticals Inc. 67 5.30 9.24M 1.15 73.62
Fate Therapeutics Inc. 15 0.00 63.28M -1.23 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 shows us the return on assets, net margins and return on equity of both businesses.

Net Margins Return on Equity Return on Assets
ANI Pharmaceuticals Inc. 13,838,550.25% 7% 3.1%
Fate Therapeutics Inc. 431,062,670.30% -54.3% -39.2%

Risk and Volatility

A 2.16 beta means ANI Pharmaceuticals Inc.’s volatility is 116.00% more than Standard and Poor’s 500’s volatility. Competitively, Fate Therapeutics Inc.’s 62.00% volatility makes it more volatile than Standard and Poor’s 500, because of the 1.62 beta.

Liquidity

0.9 and 0.7 are the respective Current Ratio and a Quick Ratio of ANI Pharmaceuticals Inc. Its rival Fate Therapeutics Inc.’s Current and Quick Ratios are 6.4 and 6.4 respectively. Fate Therapeutics Inc. has a better chance of clearing its pay short and long-term debts than ANI Pharmaceuticals Inc.

Analyst Recommendations

ANI Pharmaceuticals Inc. and Fate Therapeutics Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ANI Pharmaceuticals Inc. 0 0 2 3.00
Fate Therapeutics Inc. 0 1 5 2.83

$75.5 is ANI Pharmaceuticals Inc.’s consensus price target while its potential upside is 26.51%. Meanwhile, Fate Therapeutics Inc.’s consensus price target is $24.83, while its potential upside is 75.73%. Based on the data given earlier, Fate Therapeutics Inc. is looking more favorable than ANI Pharmaceuticals Inc., analysts view.

Institutional and Insider Ownership

Roughly 86.2% of ANI Pharmaceuticals Inc. shares are owned by institutional investors while 98.8% of Fate Therapeutics Inc. are owned by institutional investors. 3.3% are ANI Pharmaceuticals Inc.’s share owned by insiders. Competitively, insiders own roughly 0.9% of Fate Therapeutics Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ANI Pharmaceuticals Inc. 1.72% 2.27% 20.43% 55.98% 25.49% 87.89%
Fate Therapeutics Inc. -0.23% 3.72% 35.11% 49.39% 152% 71.86%

For the past year ANI Pharmaceuticals Inc. was more bullish than Fate Therapeutics Inc.

Summary

ANI Pharmaceuticals Inc. beats Fate Therapeutics Inc. on 8 of the 13 factors.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for pain; Propafenone to treat arrhythmia; Propranolol ER and Inderal LA for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. The companyÂ’s immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf T-cell immunotherapies; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.